Dipraglurant
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.
Link from a Wikipage to another Wikipage
primaryTopic
Dipraglurant
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.
has abstract
Dipraglurant (INN) (code name ...... of non-parkinsonian dystonia.
@en
CAS number
872363-17-2
FDA UNII code
CV8JZR21A1
PubChem
Wikipage page ID
44,864,244
page length (characters) of wiki page
Wikipage revision ID
995,962,990
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
ChemSpiderID
25,069,676
IUPAC name
PubChem
44,557,636
SMILES
c1ccncC#CCCc2cn3ccF
@en
StdInChIKey
LZXMUJCJAWVHPZ-UHFFFAOYSA-N
@en
UNII
CV8JZR21A1
@en
wikiPageUsesTemplate
hypernym
comment
Dipraglurant (INN) (code name ...... of non-parkinsonian dystonia.
@en
label
Dipraglurant
@en